Get the content you want anytime you want.
The Best Infectious Disease News Delivered Weekly

The Contagion® Influenza specialty page provides influenza-specific clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.


E-cigarette Users, Especially Women, May Be More Susceptible to Flu
Early research found that e-cigarette use affects the immune system response to the flu virus and the effects are different for female and male users.
Investigators Discover Unknown Achilles Heel of Influenza Virus
In an unexpected discovery, a NIAID-funded study team has found that a human antibody can target a part of the hemagglutinin protein that the influenza virus uses to enter and infect cells.
Oseltamivir Pre-Exposure Prophylaxis Does Not Cut Influenza Rates in Lung Transplant Recipients
A team of investigators from the University of North Carolina Medical Center found that oseltamivir prophylaxis did not reduce the rate of influenza within the first year following a lung transplant.
Glecaprevir and Pibrentasvir Approved to Treat Hepatitis C in Children
The FDA has approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all 6 genotypes of hepatitis C in children 12 to 17 years. 
US Flu Activity Falls Below Baseline After Longest Flu Season in a Decade
A 21-week-long flu season begins to wind down while investigators find that flu infections in consecutive seasons are more likely in young children.
Takeaways From a 10-Year Mandatory Influenza Vaccine Program for Health Care Workers
The rate of health care-associated influenza cases per season decreased from a median of 16.8 cases pre-policy rollout to 5.2 cases post-policy rollout at a large pediatric hospital.
Common Food Additive May Hinder Flu Vaccine Effectiveness
Could an additive in your food be messing with the immune process that helps you fight off the flu after receiving the influenza vaccine?
Cloudbreak Antiviral Conjugate Demonstrates Potent In Vitro Activity
Cidara Therapeutics has developed CB-012, a stable conjugate of a highly potent antiviral agent linked to human IgG1 Fc, and investigators are evaluating the asset for the treatment and prevention of seasonal and pandemic influenza A and B infections.
Big advances in treatment can't make up for an inability to stop new infections, which number 5,000 per day worldwide.